Qilu Pharmaceutical Romiplostim price

Romiplostim (Romiplostim) has been approved by the State Food and Drug Administration for marketing. Romiplostim for injection (romiplostim biosimilar) produced by Qilu Pharmaceutical is a type of biological drug (recombinant human thrombopoietin peptidomimetic for injection-Fc Fusion protein), has been applied for marketing after clinical trials for the treatment of immune thrombocytopenia (ITP). This is the first domestic generic version of romiplostim to be applied for marketing after the original research was launched.

Romiplostim increases platelet counts in healthy subjects andITP patients in a dose-dependent manner. PhysiologicalTPO elevation occurs in the context of reduced platelet production, resulting in reduced TPO clearance. In response to the acute increase in TPO concentration, megakaryocyte colony-forming cells differentiate into mature megakaryocytes, and platelet counts begin to increase around day 5 and peak after 10 days. Therefore, pharmacodynamic studies indicate that TPO-RAs, including romiplostim, typically require at least 5-7 days to produce clinically significant increases in platelet counts. The risk of bleeding was highest during dose escalation. Patients who started taking romiplostim at a starting dose of 4.5 g/kg/week had fewer bleeding events, shorter hospital stays, and an increased rate of platelet counts ⩾50 × 109/L without thrombotic events.

RomigrastimThe original drug has not been included in the scope of medical insurance due to its short time on the market. It may be difficult to purchase it in China. The price of the original version in Hong Kong may be RMB 10,000 per pill (the price may fluctuate due to exchange rates). The price of the European version of romiplostim the original drug may be 11,000 RMB per pill, the German version may be 9,850 RMB per pill, and the Hong Kong version may be 8,900 RMB per pill (the price may fluctuate due to the exchange rate). The ingredients of the drugs are basically the same. For specific prices and drug details, please consult Yaode’s medical consultant.